New hope for tough pancreatic cancer: combo therapy with or without radiation
NCT ID NCT06662006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced pancreatic cancer that has spread and is no longer helped by first-line chemotherapy. It tests a mix of drugs (nal-IRI, 5-FU, leucovorin, benmelstobart, and anlotinib) with or without focused radiation (SBRT). The goal is to see if this combination can shrink or control tumors. About 56 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, 025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.